Navigation Links
American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
Date:5/21/2008

d('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >ELRN) and RDC Rafael Development Corporation, Ltd. For more information, please visit http://www.galilmedical.com

NOTE:

"Galil Medical has received approval from Elron Electronic Industries Ltd. (NASDAQ: ELRN) to have the announcement associated with its ticker. Please associate this announcement also to the ELRN ticker."

Contact:

Pam Schwartz

Communications Manager

Galil Medical

T: +972-4-909-3273

M: +972-52-625-4443

F: +972-4-959-1077

pam.schwartz@galilmedical.com


'/>"/>
SOURCE Galil Medical Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Coalition for Pulmonary Fibrosis and American Thoracic Society Continue Research Partnership Through 2010
2. Elseviers Engineering Village Search Platform Combines the American Geological Institutes Georef Database With Google Maps
3. American Oriental Bioengineering Forms Science and Technology Advisory Committee
4. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
5. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
6. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
7. American Oriental Bioengineering Comments on Earthquake
8. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
9. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
10. LifeQuest World Launches Immune System Boosting Supplement to the North American Market
11. American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health
Post Your Comments:
*Name:
*Comment:
*Email: